Nov. 23, 2010
NewsCompany News

Neurological Disease Research

Evotec Collabortes with Merck KGaA

Evotec announced that it has signed within the "NEU²-Consortium" framework and partially funded by the Federal Ministry of Education and Research (Bundesministerium fuer Bildung und Forschung - BMBF), an agreement with Merck KGaA, Darmstadt, Germany, to develop pre-clinical candidates for an undisclosed neurological disease. Evotec will provide drug discovery expertise covering in vitro biology, medicinal chemistry and in vitro and in vivo pharmacology. As part of the collaboration, Evotec will apply their integrated drug discovery expertise and technologies to identify interesting small molecules for the selected target. The molecules will be further optimised and progressed through lead optimization to a pre-clinical candidate.

Related News on NEU²-Consortium: Multiple Sclerosis: Research Agreement Signed

Register now!

The latest information directly via newsletter.

To prevent automated spam submissions leave this field empty.